October 2014—The bioT3 Metastatic Cancer Solution from BioTheranostics now includes a single assay that covers genetic mutations and protein expression. CancerTreatment NGS+ is a multiplatform approach that combines next-generation sequencing with selected IHC and FISH tests to identify biomarkers linked to targeted treatments.
BioTheranostics, 877-886-6739